QURE News & Analysis

uniQure (QURE) Plunges 65% on Missed 48-Month Gene Therapy Data

uniQure (QURE) shares fell by 65% following the announcement that the 48-month data for its Huntington's disease gene therapy did not meet key effectiveness statistics. The firm had hoped to demonstrate significant long-term benefits from its treatment, but the results have raised concerns among investors. This steep decline reflects market reactions to unmet clinical expectations. The missed metrics could impact future funding and development of gene therapies, stressing the need for precise outcomes in clinical trials.